Oil and Gas - The Mother of Inflation - GineersNow Petroleum magazine

following the patient’s first infusion. Additional
enrollment continues. INOVIO (NASDAQ:
INO),
a biotechnology company focused on
bringing to market precisely designed
DNA medicines to treat and protect people
from infectious diseases and cancer, and
Advaccine Biopharmaceuticals Suzhou Co.,
Ltd. (“Advaccine”), an emerging biotech
company with next-generation technology in
vaccines, both preventive and therapeutic,
recently announced that they have entered
into a collaboration and license agreement for
COVID-19 DNA vaccine candidate INO-4800.
Under the collaboration and license
agreement, Advaccine will have the
exclusive right to develop, manufacture
and commercialize INO-4800 within Greater
China, inclusive of Mainland China, Hong
Kong, Macao, and Taiwan. Advaccine will
license its plasmid manufacturing process for
use with INO-4800 and other INOVIO pipeline
product candidates to INOVIO with the right
to sublicense to INOVIO’s manufacturing
partners. Additionally, Advaccine will provide
its clinical data to INOVIO in support of
INOVIO’s global INO-4800 regulatory filings
and INOVIO will provide its INO-4800 clinical
data for Advaccine to incorporate into its
marketing applications in Greater China
Advaccine will make to INOVIO an upfront
payment of $3.0 million as well as pay
an aggregate of $108.0 million upon the
achievement of specified development
and sales-based milestones for INO-4800
in Greater China. INOVIO will be entitled to
receive a royalty equal to a high single-digit
percentage of annual net sales in each region
within Greater China.
CytoDyn Inc. (OTCQB: CYDY),
a late-stage biotechnology company
developing Vyrologix (leronlimab-PRO 140),
a CCR5 antagonist with the potential for
multiple therapeutic indications, announced
this month a research manuscript submitted by
Nicholas J. Agresti, M.D. has been accepted
for publication in the Journal of Translational
Autoimmunity. Dr. Agresti’s research findings
were based on four critically ill COVID-19
patients treated with leronlimab under eIND.
The manuscript Ms.
No. JTAUTO-D-20- 00043R1 is entitled
“Disruption of CCR5 Signaling to Treat
COVID-19-Associated Cytokine Storm: Case
Series of Four Critically Ill Patients Treated
with Leronlimab.” Nicholas J. Agresti, M.D.,
stated, “We are very thankful with the clinical
outcomes for these patients and are honored
by the acceptance of our research for
publication. We hope this work will continue
to advance research to understand how to
effectively mitigate the effects of COVID-19.”
Novavax, Inc.
(NASDAQ: NVAX),
a late-stage biotechnology company
developing next-generation vaccines
for serious infectious diseases, recently
announced that it has finalized an agreement
with the Government of Canada to supply up
to 76 million doses of NVX-CoV2373, the
company’s recombinant protein-based
COVID-19 vaccine. Canada has committed to
purchase 52 million doses of the vaccine with
the option for up to an additional 24 million
doses. NVX-CoV2373 is currently in Phase
3 clinical development for the prevention of
COVID-19. “We thank the
Government of Canada for their confidence
in our program and ongoing partnership in
the regulatory review and delivery of a safe,
effective COVID-19 vaccine for the citizens
of Canada,” said John J. Trizzino, Chief
Commercial Officer and Chief Business
Officer, Novavax. “Novavax is proud to play
our part in working tirelessly together with
governments, scientists, regulators and
others in the global effort to put an end to the
pandemic.” The company expects to supply
NVX-CoV2373 to Canada beginning as early
as the second quarter of 2021, following
authorization by Canada’s regulatory agency.
101